US-based, Kali Extracts (KALY) has confirmed efforts to evaluate its proprietary CBD extract formulation as a treatment for coronavirus symptoms.
KALY’s proprietary CBD formulation has been developed for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company’s U.S. Patented Cannabis Extraction Process.
As detailed in a recently published research study (Journal of Cannabis Research) the KALY U.S. Patented CBD extract provides significant anti-inflammatory responses in vitro.
The next phase of research is now moving forward in preclinical in vivo research to expand evaluation of the effects on lung function, total body distribution, whole body clearance of the extract and dosage evaluations for maximal efficacy. KALY has filed a new patent application specifically on its CBD formulation for symptoms associated with COPD and other similar respiratory conditions.
Although it is unlikely that the company will be able to prove efficacy within the time frame of the current coronavirus outbreak, the wider potential for being able to treat pulmonary symptoms associated with viruses of this nature is significant. COPD is a chronic condition, that is hugely expensive for health systems to treat so should Kali be able to demonstrate the effectiveness of their formulation, then the market potential is substantial.
Source: Kali Extracts